<DOC>
	<DOCNO>NCT00173706</DOCNO>
	<brief_summary>This study design test hypothesis treatment L-carnitine improve quality life specific symptom sign patient renal failure submit hemodialysis .</brief_summary>
	<brief_title>Evaluation Effects L-Carnitine Injection Patients Undergoing Hemodialysis</brief_title>
	<detailed_description>L-Carnitine naturally occur compound facilitate transport fatty acid mitochondria beta-oxidation . A lack carnitine hemodialysis patient cause insufficient carnitine synthesis particularly loss dialytic membrane , lead patient carnitine depletion relative increase esterify form . Many study show L-carnitine supplementation lead improvement several complication see uremic patient , include cardiac complication , impaired exercise functional capacity , muscle symptom , increase symptomatic intradialytic hypotension , erythropoietin-resistant anemia , normalize reduce carnitine palmitoyl transferase activity red cell .</detailed_description>
	<mesh_term>Hypotension</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Paresis</mesh_term>
	<criteria>Patients follow criterion eligible participation study : 1 . Male female adult 18 year age 2 . On hemodialysis least one year 3 . Interdialysis weight gain &lt; 5 % 4 . Bicarbonate dialysis 3 time per week 5 . Modality dialysis unchanged 3 month prior entry study ( concern dialysistime mode : bicarbonate , acetate dialysis ) 6 . Have one follow symptom sign respond diet pharmacological intervention : 1. persistent weakness affect daily life 2. malnutrition 3. anemia ( hemoglobin [ Hb ] &lt; 12 g/dl ; hematocrit [ Hct ] &lt; 30 % ) 4. experience intradialytic complication ( cramp , muscular pain , hypotension , hypertension , headache ) 7 . On regular treatment vitamin B12 folates 8 . Normal iron status ( ferritin &gt; 100 ng/ml ; transferrin saturation [ TSAT ] &gt; 20 % ) 9 . Informed consent obtain 10 . Patients diabetes mellitus allow enter study stable glycaemic control diet pharmacological treatment . Patients display one follow criterion eligible participation study : 1 . Severe uncontrolled hypertension ( systolic &gt; 170 ; diastolic &gt; 115 ) outside dialysis 2 . Some patient echocardiogram ( ECHO ) define chronic heart failure . Patients New York Heart Association ( NYHA ) class II class III admit . Patients class IV must exclude . Some patient angina . Patients stable effort angina well control treatment recruit . Absolute exclusion angina rest . 3 . Major hepatic disease chronic active ( aggressive ) hepatitis cirrhosis 4 . Systemic haematological disease tumours 5 . Uncontrollable diabetes 6 . History drug alcohol abuse 7 . Positive screen HIV antibody 8 . Life expectancy less one year 9 . Uncontrolled hyperparathyroidism ( patient stable bone status recruit ) 10 . Use immunodepressants precede 4 week 11 . Changes corticoid therapy precede 4 week 12 . Use experimental drug precede 4 month 13 . Use Lcarnitine precede 4 month 14 . Informed consent obtain 15 . Pregnancy 16 . Patients already include clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>L-Carnitine</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>cardiac complication</keyword>
	<keyword>impaired exercise functional capacity</keyword>
	<keyword>muscle symptom</keyword>
	<keyword>intradialytic hypotension</keyword>
	<keyword>erythropoietin-resistant anemia</keyword>
</DOC>